- Home
- BTT vs IMCR Comparison
BTT vs IMCR Comparison
Compare BTT & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTT | IMCR |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2011 | 2016 |
Fundamental Metrics
Financial Performance| Metric | BTT | IMCR |
|---|---|---|
| Price | $22.65 | $28.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $66.33 |
| AVG Volume (30 Days) | 69.9K | ★ 368.5K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | N/A | $14.57 |
| Revenue Next Year | N/A | $8.21 |
| P/E Ratio | ★ N/A | $115.04 |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $21.42 | $27.56 |
| 52 Week High | $23.24 | $40.71 |
Technical Indicators
Market Signals| Indicator | BTT | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 43.94 | 42.05 |
| Support Level | $22.48 | N/A |
| Resistance Level | $22.75 | $31.56 |
| Average True Range (ATR) | 0.15 | 1.26 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 40.32 | 15.85 |
Price Performance
Historical ComparisonAbout BTT BlackRock Municipal 2030 Target Term Trust
Blackrock Municipal 2030 Target Term Trust is a United States-based closed-end management investment company. The investment objective of the company is to provide current income exempt from regular federal income tax and to return $25.00 per common share to holders of common shares. The trust seeks to achieve its investment objectives by investing a majority of its assets in municipal bonds exempt from U.S. federal income taxes.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.